Alzamend Neuro receives final full data set from AL001 trial

Alzamend Neuro announced that it has received the final full data set from its multiple ascending dose clinical trial for AL001 treatment of dementia related to Alzheimer’s. Building on the promising preliminary results released in June 2023, Alzamend’s full data set confirms the successful determination of a maximum tolerated dose for AL001. Identified by an independent safety review committee, this MTD represents a pivotal step forward; it delivers lithium at a lithium carbonate equivalent dose of 240 mg, taken three times daily. This is an AL001 formulation that will unlikely require the need for traditional lithium therapeutic drug monitoring. This innovation is specifically designed to address the needs of fragile populations, such as elderly and Alzheimer’s patients, by offering a potentially more efficient and safer alternative to existing treatments.